MEASUREMENT OF CYCLOPHILIN A AS A NEW BIOMARKER FOR DIABETIC NEPHROPATHY IN TYPE II DIABETES MELLITUS
Prof .Dr. Mohy Eldin Abd EL-Fattah Abd EL-Atty¹
1Faculty of Science, Suez Canal University, Egypt
Dr. Sara Abd EL-Monem Aboelroos²
2Faculty of Medicine, Suez Canal University, Egypt
Faten Abdelmonem Metwalli Mohamed³
3Faculty of Science, Suez Canal University, Egypt
Diabetic nephropathy (DN) is a serious and progressive complication related to diabetes. It can increase the risk and progression of end-stage renal disease. Diabetic nephropathy is clinically defined as a rise in urinary albumin excretion microalbuminuria (30-300mg albumin/gm creatinine) then macroalbuminuria (>300mg albumin/gm creatinine), decreased glomerular filtration rate (GFR) and elevated blood pressure.1Albuminuria have some limitations to detect early stages of DN such as it can be elevated in some cases such as exercise, acute illness, heart failure and there are some diabetic patients develop DN with normal albuminuria2so, new biomarkers are required. CyPA is an intracellular protein has various intracellular functions such as intracellular signaling, protein trafficking, and regulating the activity of other proteins.3CyPA was revealed to be secreted by monocytes in response to hyperglycemia in diabetic patients indicating that secreted CyPA could be a potential secretary marker in type II diabetes mellitus.4 Furthermore, a relatively high expression of CyPA in normal kidneys may be associated with kidney damage.5 Serum CyPA can be used as a potential biomarker of DN and may be raised earlier than albuminuria.
This is a case-control study to detect the validity of using cyclophilin A as an earlier and reliable biomarker for diabetic nephropathy. In this study 112 subjects were enrolled and divided into three groups;
– The first group was healthy control group included 16 subjects (14.3% of the study population).
-The second group was diabetic patients without nephropathy (stage0) with no evidence of renal disease included 16 subjects (14.3% of the study population).
-The third group was diabetic nephropathy patients included 80 subjects represented 71.4% of the study population divided into five stages;
• Stage1 DN patients having normoalbuminuria (ACR